Shintaro Kanda

5.4k total citations
134 papers, 1.9k citations indexed

About

Shintaro Kanda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Shintaro Kanda has authored 134 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 83 papers in Pulmonary and Respiratory Medicine and 22 papers in Epidemiology. Recurrent topics in Shintaro Kanda's work include Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (43 papers) and Cancer Immunotherapy and Biomarkers (28 papers). Shintaro Kanda is often cited by papers focused on Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (43 papers) and Cancer Immunotherapy and Biomarkers (28 papers). Shintaro Kanda collaborates with scholars based in Japan, United States and United Kingdom. Shintaro Kanda's co-authors include Hidehito Horinouchi, Noboru Yamamoto, Yutaka Fujiwara, Yuichiro Ohe, Hiroshi Nokihara, Yasushi Goto, Tomonobu Koizumi, Tomohide Tamura, Koji Tsuta and Masanori Yasuo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Shintaro Kanda

121 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shintaro Kanda Japan	24	1.3k	1.1k	258	232	217	134	1.9k
Dwight H. Owen United States	22	1.4k 1.1×	651 0.6×	289 1.1×	313 1.3×	158 0.7×	110	1.9k
Lorenzo Antonuzzo Italy	23	1.3k 1.0×	609 0.6×	329 1.3×	404 1.7×	253 1.2×	173	1.9k
Myung‐Ju Ahn South Korea	20	792 0.6×	990 0.9×	250 1.0×	165 0.7×	96 0.4×	75	1.5k
Flavia Longo Italy	26	998 0.8×	910 0.8×	390 1.5×	185 0.8×	209 1.0×	71	2.0k
Giuseppe Lo Russo Italy	24	1.3k 1.0×	731 0.7×	567 2.2×	232 1.0×	98 0.5×	145	2.0k
Ke‐Neng Chen China	21	882 0.7×	1.0k 1.0×	272 1.1×	149 0.6×	126 0.6×	77	1.7k
Lavinia Spain United Kingdom	15	1.9k 1.5×	646 0.6×	304 1.2×	352 1.5×	179 0.8×	61	2.4k
Matias Riihimäki Sweden	12	1.4k 1.1×	821 0.8×	348 1.3×	378 1.6×	164 0.8×	12	2.2k
Antoine Adenis France	24	698 0.5×	1.1k 1.0×	289 1.1×	128 0.6×	269 1.2×	84	2.0k
Héctor Soto Parrà Italy	24	1.3k 1.0×	1.6k 1.5×	258 1.0×	73 0.3×	135 0.6×	101	2.3k

Countries citing papers authored by Shintaro Kanda

Since Specialization

Citations

This map shows the geographic impact of Shintaro Kanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shintaro Kanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shintaro Kanda more than expected).

Fields of papers citing papers by Shintaro Kanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shintaro Kanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shintaro Kanda. The network helps show where Shintaro Kanda may publish in the future.

Co-authorship network of co-authors of Shintaro Kanda

This figure shows the co-authorship network connecting the top 25 collaborators of Shintaro Kanda. A scholar is included among the top collaborators of Shintaro Kanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shintaro Kanda. Shintaro Kanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsutsui, Toshiharu, Toshihiko Agatsuma, Manabu Yamamoto, et al.. (2025). Real-world data after introduction of chemoimmunotherapy in patients with extensive-disease small cell lung cancer: A multicenter retrospective study. Respiratory Investigation. 63(5). 928–933.

Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations

Kanda, Shintaro, Toshihiko Agatsuma, Yumiko Kakizaki, et al.. (2024). EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study. Respiratory Investigation. 62(2). 262–268. 4 indexed citations

Kanda, Shintaro, et al.. (2024). Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review. Respiratory Investigation. 62(4). 677–680.

Kobayashi, Takashi, Shintaro Kanda, Kazunari Tateishi, et al.. (2023). EGFR mutation and ALK fusion-positive non-small cell lung cancer: a multicenter prospective cohort study in Nagano Prefecture, Japan. Oncology in Clinical Practice. 19(5). 339–345.

Kanda, Shintaro, et al.. (2023). Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Japanese Journal of Clinical Oncology. 53(7). 547–561. 41 indexed citations

Horinouchi, Hidehito, Aya Kuchiba, Yuji Matsumoto, et al.. (2022). Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. Journal of Cancer Research and Clinical Oncology. 149(7). 3185–3191. 1 indexed citations

Kobayashi, Takashi, et al.. (2021). Thymic epithelial tumor with superior vena cava syndrome diagnosed by percutaneous endovascular tumor biopsy: A report of two cases. Respiratory Investigation. 59(5). 695–699. 1 indexed citations

Murakami, Shuji, Ryota Shibaki, Yuji Matsumoto, et al.. (2020). Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody. Thoracic Cancer. 11(12). 3585–3595. 36 indexed citations

10.

Okuma, Yusuke, Yasushi Goto, Fumiyoshi Ohyanagi, et al.. (2020). Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Medicine. 9(20). 7418–7427. 14 indexed citations

11.

Kanda, Shintaro, Yuichiro Ohe, Yasushi Goto, et al.. (2020). Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer. Cancer Science. 111(6). 1933–1942. 12 indexed citations

12.

Horinouchi, Hidehito, Yuji Matsumoto, Shuji Murakami, et al.. (2019). Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer. Thoracic Cancer. 10(5). 1141–1148. 7 indexed citations

13.

Makino, Yoshinori, Hitoshi Sato, Yasushi Goto, et al.. (2019). Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer. Cancer Science. 110(11). 3573–3583. 3 indexed citations

14.

Tanaka, Midori, Hidehito Horinouchi, Yasushi Goto, et al.. (2018). Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. ESMO Open. 3(4). e000342–e000342. 10 indexed citations

15.

Shinno, Yuki, Yasushi Goto, Sho Watanabe, et al.. (2018). Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open. 3(7). e000399–e000399. 5 indexed citations

16.

Kanda, Shintaro, Yasushi Goto, Hidehito Horinouchi, et al.. (2018). Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. 124. 179–188. 58 indexed citations

17.

Kanda, Shintaro, et al.. (2017). Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer. Translational Cancer Research. 6. 2 indexed citations

18.

Okuma, Hitomi Sumiyoshi, Hidehito Horinouchi, Shinsuke Kitahara, et al.. (2016). Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer. Clinical Lung Cancer. 18(2). 234–240.e2. 7 indexed citations

19.

Katsuya, Yuki, Hidehito Horinouchi, Tetsuhiko Asao, et al.. (2016). Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer. 99. 4–10. 76 indexed citations

20.

Horinouchi, Hidehito, Yasushi Goto, Shintaro Kanda, et al.. (2015). Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. International Journal of Radiation Oncology*Biology*Physics. 94(1). 155–162. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact